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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016based on the assumption that a corresponding autoantibody is
present and that the respective antigen is upregulated in the
inﬂamed kidney in LN. Known autoantibodies were retrieved from
Pubmed and expression levels of the respective targets were
retrieved from the GEO database.
Results: TCRß repertoire analysis demonstrated the presence of an
oligoclonal T cell population in the urine of patients with LN,
indicative of an antigen speciﬁc T cell response. However no T cell
response against lysates from healthy kidney tissue was detectable
in SLE patients, suggesting intact immune tolerance against normal
kidney tissue. Using an algorithm combining known targets of LN
associated autoantibodies and upregulation of these structures in
LN, 8 candidate renal autoantigens were identiﬁed. Of these auto-
antigens Vimentin was selected for a set of pilot experiments. Using
T cell libraries autoreactive CD4+ T cells reacting with Vimentin
were identiﬁed in 4 patients with active LN. In inactive SLE pa-
tients only few Vimentin reactive CD4+ T cells were observed
while no Vimentin speciﬁc T cells were detected in healthy
controls.
Conclusions: In LN there is no major breach of T cell immune
tolerance against “normal” kidney antigens. However CD4+ T cells
reactive with renal proteins with increased expression in LN are
detectable and presumably perpetuate the local renal inﬂammation.
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GermanyS22Introduction: Mesenchymal stromal cells (MSC) are extensively
studied as potential therapeutic modulators of disease. CD362/
syndecan-2 is a heparan sulphate proteoglycan identiﬁed as a
functional marker for MSC isolation and therapeutic development.
These are present in both bone marrow derived MSC and umbilical
cord stromal cells. However, their therapeutic potential in diabetic
nephropathy is yet unclear. We speculated that a single dose of
CD362+ MSC could have beneﬁts in diabetic kidney disease.
Methods: LepRdb/db type 2 diabetic male mice were procured
from Taconic Biosciences (DK-8680 Ry, Denmark). At six weeks of
age uninephrectomy was performed to accelerate diabetic kidney
disease via increased hyperﬁltration. At 4 months of age only
proteinuric mice were randomized to either a single intravenous
dose of 250,000 CD362+ MSC or saline. 56 days later kidneys were
collected for immunostaining, ﬂow cytometry, ELISA and RT-PCR.
Proteinuria was assessed as albumin to creatinine ratio in spot urine
samples. Bio-distribution of MSC after injection was studied in
various organs at 4, 14, 28, and 56 days by detecting human DNA
(ALU) sequences in mouse tissues.
Results: LepRdb/db type 2 diabetic male mice showed increased
urine albumin/creatinine ratio, plasma creatinine, BUN levels and
decreased GFR levels versus baseline. This was associated with
diffuse glomerulosclerosis. Renal IL-6, TNF- , and iNOS mRNA
expression were signiﬁcantly increased in vehicle-treated mice.
CD362+ MSC-treated mice revealed a signiﬁcant reduction in glo-
merulosclerosis, albuminuria, plasma creatinine, BUN levels, and
showed a signiﬁcantly increased GFR. The markers of inﬂammation
were signiﬁcantly compared to vehicle-treated mice and reached
baseline level. Human DNA was not detectable in any organ tissue
at 4 days after injection or later.
Conclusions: Human CD362+MSC do not persist 4 days or more
upon injection in diabetic mice. Nevertheless, CD362+ MSC were
able to protect the type 2 diabetic mice with kidney disease through
modulation of inﬂammation. Our studies were based on single MSC
injections, as the MSC did not persist in the tissue, repetitive in-
jections might be even more effective. We conclude that a single
injection of CD362+ MSC can have beneﬁcial effects on diabetic
nephropathy via a systemic effect.Kidney International Reports (2016) 1, S1–S22
